All In Biotech

Drug Trial Radar · NCT01656343

Belatacept and Risk of Post-transplant Lymphoproliferative Disorder in US Renal Transplant Recipients

Belatacept and Risk of PTLD in US Renal Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Jul 22, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

775

Actual

Start

Oct 31, 2011

Primary completion

Aug 5, 2019

Study completion Aug 5, 2019

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Aug 3, 2012

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

* To estimate the incidence rates of post-transplant lymphoproliferative disorder (PTLD) in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept at the time of transplantation * To estimate the incidence rates of PTLD in adult, EBV seropositive, kidney alone transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the time of transplantation * To compare the PTLD incidence rates in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept to the rates in adult, EBV seropositive, kidney alone transplant recipients treated with CNI-based regimens at the time of transplantation

Conditions

  • Kidney Transplantation
  • Transplantation, Kidney

Interventions

  • Calcineurin inhibitors (CNI)Drug

    No Intervention

  • BelataceptDrug

    No Intervention

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence rates of post-transplant lymphoproliferative disorder (PTLD) in adult, EBV seropositive, kidney alone transplant recipients treated with belatacept at the time of transplantationTime frame: Every 6 months for up to 72 months
  2. Incidence rates of PTLD in adult, EBV seropositive, kidney alone transplant recipients treated with calcineurin inhibitors (CNI)-based regimens at the time of transplantationTime frame: Every 6 months for up to 72 months
  3. Ratio for PTLD incidence rates in adult, EBV seropositive, kidney alone, belatacept treated patients and adult EBV seropositive, kidney alone, CNI-treated patients at the time of transplantationTime frame: Every 6 months for up to 72 months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.